These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7051805)

  • 1. A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.
    Ahmann DL; O'Fallon JR; Scanlon PW; Payne WS; Bisel HF; Edmonson JH; Frytak S; Hahn RG; Ingle JN; Rubin J; Creagan ET
    Am J Clin Oncol; 1982 Aug; 5(4):371-81. PubMed ID: 7051805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer.
    Ahmann DL; Scanlon PW; Bisel HF; Edmonson JH; Frytak S; Payne WS; O'Fallon JR; Hahn RG; Ingle JN; O'Connell MJ; Rubin J
    Lancet; 1978 Apr; 1(8070):893-6. PubMed ID: 76842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Rubens RD; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Hayward JL; Knight RK; Bulbrook RD
    Recent Results Cancer Res; 1984; 96():74-89. PubMed ID: 6396780
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
    Rivkin SE; Glucksberg H; Foulkes M
    Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
    Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
    Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable factors in the adjuvant therapy of breast cancer.
    Carpenter JT; Maddox WA; Laws HL; Wirtschafter DD; Soong SJ
    Cancer; 1982 Jul; 50(1):18-23. PubMed ID: 7044517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
    J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
    Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant systemic therapy in primary breast cancer.
    Mouridsen HT; Palshof T
    Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
    Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
    Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Redmond C; Fisher ER; Wolmark N
    NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
    Knight WA; Rivkin SE; Glucksberg H; Foulkes MA; Costanzi JJ; Stephens RL; Athens JW; O'Bryan RM
    Breast Cancer Res Treat; 1983; 3 Suppl():S27-33. PubMed ID: 6367857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
    Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
    Jones SE; Moon TE; Bonadonna G; Valagussa P; Rivkin S; Buzdar A; Montague E; Powles T
    Am J Clin Oncol; 1987 Oct; 10(5):387-95. PubMed ID: 3310603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.